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Abstract
H3N2 influenza viruses have now circulated in the human population for 43 years since the pandemic of 1968, accumulating
sequence changes in the hemagglutinin (HA) and neuraminidase (NA) that are believed to be predominantly due to
selection for escape from antibodies. Examination of mutations that persist and accumulate led to identification of
antigenically significant mutations that are contained in five antigenic sites (A–E) mapped on to the H3 HA. In early H3N2
isolates, antigenic site A appeared to be dominant while in the 1990s site B seemed more important. To obtain experimental
evidence for dominance of antigenic sites on modern H3 HAs, we have measured antibodies in plasma of human subjects
who received the 2006–07 trivalent subunit influenza vaccine (H3 component A/Wisconsin/67/05) or the 2008–09
formulation (H3 component A/Uruguay/716/07). Plasmas were tested against expressed HA of Wisconsin-like influenza A/
Oklahoma/309/06 and site-directed mutants in antigenic site A (NNES121-124ITEG, N126T, N133D, TSSS135-138GSNA, K140I,
RSNNS142-146PGSG), and antigenic site B (HL156-157KS, KFK158-160GST, NDQI189-192QEQT, A196V). ‘‘Native ELISA’’
analysis and escape mutant selection with two human monoclonal antibodies demonstrated that antibody E05 binds to
antigenic site A and 1_C02 binds to site B. We find that most individuals, after vaccination in seasons 2006–07 and/or 2008–
09, showed dominance of antigenic site B recognition over antigenic site A. A minority showed dominance of site A in 2006
but these were reduced in 2008 when the vaccine virus had a site A mutation. A better understanding of
immunodominance may allow prediction of future antigenic drift and assist in vaccine strain selection.
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Introduction
Influenza viruses are major pathogens that cause seasonal
epidemics and global pandemics. Each year in the United States
more than 200,000 people are hospitalized and 20,000–36,000
people die from flu-related complications [1]. Due to rapid
accumulation of mutations to escape host defense mechanisms, the
vaccine components must be frequently updated to protect the
human population against influenza. There are three types of
influenza viruses, A, B and C. Type A viruses are divided into
subtypes according to cross-reactivity of sera with viral surface
glycoprotein antigens; to date these are subtypes H1 to H16 of the
hemagglutinin (HA) and N1 to N9 of neuraminidase (NA)
although an H17 has been recently proposed [2]. H1N1 and
H3N2 along with type B viruses are currently circulating in the
human population and these are the antigens in the trivalent
vaccines. HA is involved in two steps of the process of influenza
infection. It binds the virus to sialic acid residues of glycoproteins
or perhaps glycolipids that act as receptors on host cells then,
following endocytosis, HA mediates the fusion of viral and cellular
membranes to allow release of the viral genome-polymerase
complex into the cell (reviewed by Skehel and Wiley [3]).
Neutralizing antibodies directed against the hemagglutinin are
considered the most protective against influenza virus infection
and vaccine responses are most commonly tested by hemagglu-
tination-inhibition assays.
To escape from neutralizing antibodies produced in response to
infection and, most recently, mass vaccination, changes in HA
have accumulated in a process named antigenic drift over the 43
years since the H3N2 subtype of influenza virus was first isolated
from humans in 1968. From 1968 to 2010 there have been 108
amino acid changes identified at 63 residue positions in HA1 (total
length 328 amino acids) in the major epidemic strains and most of
these changes are considered to result from antigenic drift because
the majority (85.5%) are clustered into regions called antigenic
sites. ‘‘Antigenic site’’ was an operational term introduced by
Gerhard and Webster [4] to describe specificities of monoclonal
antibodies (mAbs). Antibodies that competed with each other for
binding were considered to bind the same antigenic site. Webster
and Laver identified four antigenic sites on the surface of H3 HA
(A–D) by competition assays [5] and Skehel identified a fifth
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antigenic site, E [6]. Each antigenic site contains many epitopes,
structurally defined as the amino acids on the antigen that contact
amino acids of the antibody [7]. Competition between antibodies
that bind the same site suggested that epitopes in the same site are
physically overlapping but are distinct, and no one antibody
molecule binds to the whole of an antigenic site. Evidence for the
location of epitopes came from characterization of escape mutants,
selected by mAbs, that contain single amino acid substitutions that
reduce binding of the mAb to undetectable levels [6,8–11]. The
three-dimensional structure of A/Aichi/2/68 X-31 HA [12]
showed the location of escape mutations selected by monoclonal
antibodies. Assuming that the amino acid that changes in an
escape mutant is within the epitope, there was now an indication
of where the antigenic sites are located. Wiley and Wilson [9,13]
took into account the sites of all known escape mutations and their
corresponding antigenic site assignment, together with changes in
naturally circulating viruses from 1968 to the mid-1980s, to
suggest the physical boundaries of sites A–E on H3 HA, and they
compiled a directory of amino acids in each of antigenic sites A–E
(Figure 1A) [9]. This is the map we and others have been using but
it important to stress that (i) most aspects of this map were not
experimentally confirmed and (ii) we do not know if this map,
which was developed based on 1968 and 1971 isolates, applies to
currently circulating viruses. Certainly many of the amino acids on
the Wiley and Wilson list appear to be important in antigenic drift
when studied phylogenetically [14] or experimentally [15].
Some mutations in HA1 created new sites for attachment of
oligosaccharide chains and since the beginning of the Hong-Kong
pandemic period in 1968 the number of N-linked glycan
attachment sites in HA1 has increased from three to eleven.
Accumulation of oligosaccharide chains in antigenic sites has been
suggested to contribute to immune evasion [6,16–18].
Antibodies directed against the head of the HA are the most
abundant of the neutralizing antibodies after vaccination. X-ray
structures of complexes of mAb Fabs bound to HA show how
antibodies can block binding of the viral HA to sialic acid
receptors on host cells [19–21]. Antibodies were shown to bind
near the sialic acid binding site or somewhat distant but in an
orientation where the Fc portion would obstruct binding to
cellular receptors [19,22–24]. Monoclonal antibodies specific to
the more conserved stem domain of H1N1, H3N2 and H5N1
viruses have been described in recent studies [25–29]. These
antibodies have broad neutralizing activity between viral subtypes
and apparently act by blocking the conformational change that
leads to fusion [27]. The broadly neutralizing antibodies that bind
to the stem region have not been detected as a significant
component of the antibody repertoire but they were found to be
induced by a ‘‘headless’’ construct [30]. At this time vaccine
production is still re-tooled annually according to new antigenic
variants that are altered in the traditional neutralizing antigenic
sites in the receptor binding domain of HA1.
Antibodies with flat binding surfaces cannot penetrate the
receptor binding site of HA [31] but they can sterically block
receptor attachment by binding to epitopes on the loops
surrounding the sialic acid binding site [12,13]. The problem is
that mutations in these loops can abrogate antibody binding
without affecting HA function. One crystal structure shows an
anti-H1 antibody in which the CDR3 loop is long enough to enter
the receptor binding site, giving a degree of cross-reactive
neutralization among seasonal H1N1 viruses [21], but in most
cases the virus can easily escape antibody neutralization.
The presence of five independent antigenic sites on HA would
appear to mean that at least 5 amino acid sequence changes would
be needed for a new antigenic variant to emerge. In the early years
of H3N2 circulation, this appeared to be the case [13] but in
recent years the changes that necessitate a change in vaccine strain
have been fewer in number. The host immune response may be
limited to only the most immunodominant antigenic sites of HA.
Early studies of antigenic sites on HA of A/Memphis/1/71
suggested that antigenic site A was immunodominant [32]. In this
study only variants changed in antigenic site A were discriminated
by polyclonal antiserum. However, a rabbit was immunized with a
mAb-selected escape mutant of A/Memphis1/71 that had the
change G144D in HA1 and the serum was absorbed with wild
type virus so that only antibodies against the new epitope would
remain. There were not any; the changed epitope was not
immunogenic, indicating a change in immunodominance. Studies
by Temoltzin-Palacios and Thomas [33,34] showed that the
Figure 1. Antigenic structure of H3 HA. Five antigenic sites A–E are mapped on the HA1 surface of H3N2 influenza viruses. (A). Antigenic site A
(red color) and antigenic site B (blue color) are localized on the top of HA around the receptor binding pocket. (B). The ‘‘190 helix’’ and ‘‘B loop’’
create antigenic site B. The ‘‘A loop’’ is a part of antigenic site A. Figure 1A was made from PDB ID 2VIR [24] using PyMol (Schrödinger, LLC). Figure 1B
was made from an Oklahoma/309 HA structural model made by SWISS-MODEL.
doi:10.1371/journal.pone.0041895.g001
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neutralizing Ab response of CBA/Ca mice is focused on a few
regions of the HA1 subunit after intranasal infection with A/
Aichi/2/68 X-31 virus. Sequence analyses of variant viruses
isolated after a second infection of mice showed that 60% of
analyzed viral HAs had a G158E mutation and 17% contained a
D61N mutation. It was concluded that antigenic sites B and E are
immunodominant in mice infected with the X-31 virus. Six
polyclonal human plasma samples collected in 1976 with
hemagglutinin-inhibition activity against Aichi/68 showed de-
creased binding to mutants in antigenic site A [35] which
correlates with the data obtained with mouse mAbs specific to
site A discussed above. A computational study suggested that site A
was immunodominant in 1968–1971 and 1989–1995 while site B
was dominant in 1972–1987 and 1996–2003 [36]. Studies with
human sera have given mixed results of clear immunodominance
of site A in 1991 [37] and part of site B in 1998–99 sera [15] but
no clear dominance was seen in a study of sera collected in 2004
[38].
Overall, the phylogenetic analyses [14,39] and serum studies
[15,37] suggest that sites A and B are the most important in
directing antigenic drift of H3N2 human viruses, and so we have
investigated the immunogenicity of antigenic sites A and B of
recent H3 HAs. We mapped the binding of two human
monoclonal antibodies to wild type A/Oklahoma/309 HA and
mutant HAs derived from it, and we tested the reactivity of
polyclonal antibodies in human plasma samples after seasonal
vaccination in 2006 (H3N2 2006–07 component A/Wisconsin/
67/05) and/or after vaccination in 2008 (H3N2 2008–09
component A/Uruguay/716/2007), to wild type HA and mutants
in antigenic sites A and B. Our results indicate that most
neutralizing antibodies in human plasma against both vaccine
strains A/Wisconsin/67/05 and A/Uruguay/716/07 are directed
to antigenic site B. We conclude that antigenic site B is
immunodominant over site A in recently circulating H3N2 viruses
and that site B mutations may drive the next antigenic drift.
Results
Design of mutants
For this study we made mutations in antigenic sites A and B in
HA1. To test if mutations accumulated since 1968 have changed
the map of antigenic sites on HA and, second, to map epitopes of
monoclonal antibodies made against a recent virus, we mutated
the sequence of HA1 of a local Wisconsin-like virus, A/
Oklahoma/309/2006 (H3N2), to those amino acids in HA1 of
the earliest human H3N2 virus A/Aichi/2/1968. The mutations
are summarized in Table 1.
Expression of HA in the Bac-to-BacH expression system
Initially we expressed HA in a full-length form in mammalian
cells, but the level of HA on the cell surface was too low to reliably
quantify antibody binding. We therefore used a Baculovirus
expression system with a synthetic codon-optimized gene that
deleted the transmembrane domain and included a trimerization
sequence [40]. HA expression from the synthetic gene was greater
than 100 fold more than full-length HA expressed in mammalian
cells, and .90% of baculovirus-expressed HA was secreted into
the supernatant.
Based on this we made the HA mutants (Table 1) in the
baculovirus system. All the mutants were expressed (Figure 2). We
quantitated wild type and mutant HAs by Western blot analysis
using a commercial anti-HA tag antibody taking advantage of the
HA-tag sequence (YPYDVPDYA) that is conserved in all H3 HAs
(Figure 3).
We confirmed the correct folding of wild type and mutant HAs
expressed from baculovirus using trypsin digestion; trypsin cleaved
the expressed HA0 into HA1 and HA2 while misfolded HA would
have been degraded into small peptides [41,42].
Effect of mutations in HA of A/OK/309/06 on binding to
human monoclonal antibodies
We measured the affinity of binding of purified human
monoclonal antibodies (hmAbs) 1_C02 (D1–7) and E05 (D3–4)
[43] to wild type and mutant HAs using a native ELISA, capturing
the HA by its His6-tag to avoid denaturation (Table 2). The VH
and VL genes for hmAb E05 and 1_C02 were from single B cells of
patients vaccinated with trivalent subunit vaccine containing
H3N2 components A/California/7/04 and A/Wisconsin/67/05
X-161b) respectively. HmAbs 1_C02 and E05 bind intact virions
of A/Wisconsin/67/05 X-161b and Wisconsin-like isolate A/
Oklahoma/309/06 with high affinity but show little or no binding
to related H3N2 viruses when tested in a native ELISA (Table 3).
Our ELISA results with recombinant mutant HAs show that the
binding site of 1_C02 is site B. We found that mutations in
antigenic site B decrease the affinity of binding of mAb 1_C02 to
HA from a Kd of 1 nM in wild type to 6 nM in mutant KFK158-
160GST while there was no detectable binding to HL156-157KS.
There was no significant change in binding to NDQI186-
190QEQT and A196V. No mutations in antigenic site A affect
the binding of 1_C02. We found that E05 binds to site A.
Mutations K140I and RSNNS142-146GPGSG in antigenic site A
abolished the binding to E05 but other mutations in antigenic site
A NNES121-124ITEG, N126T, N133D and TSSS135-138GSNA
had no effect. No mutations in antigenic site B affected the binding
of E05. Our results (Table 2) show that the epitopes of human
mAbs E05 and 1_C02 are contained in antigenic sites A and B
respectively (Figure 1B). It is important to emphasize that these
epitopes do not encompass the whole of each antigenic site, which
would be physically impossible given the size of an antibody
footprint compared to the large surface areas assigned to sites A or
B.
Selection of escape mutants with human mAbs
We selected escape mutant viruses after growth of A/
Wisconsin/67/05-X161b virus in the presence of antibody
1_C02 or E05. An escape mutant virus selected by 1_C02
(EM1_C02) contains a substitution F159S in antigenic site B of
HA1. Two escape mutants selected by E05 had amino acid
substitutions at 140 (K140E and K140T) in antigenic site A. The
binding constants (Kd) are included in Table. 3. These results
confirm the binding of hmAb E05 to an epitope within site A and
of 1_C02 to an epitope within site B.
Reactivity of wild type and mutant HAs with polyclonal
antibodies in human plasma after vaccination
To test antibodies in human plasma after vaccination we used
the same panel of mutants. If antibodies in human plasma are
dominantly expressed against epitopes in antigenic site A or B we
will observe reduced binding of sera to mutants in this antigenic
site. We used 18 human plasma samples collected 6 weeks after
vaccination in Fall 2006 (H3 component A/Wisconsin/67/05)
and 11 vaccinated in Fall 2008 (H3 component A/Uruguay/716/
07). We tested binding of plasma antibodies to wild type and
mutant baculovirus-expressed HA, captured on His-tag antibody
plates to ensure preservation of native structure. The overall
avidity of binding (Kdapparent) of plasma antibodies after vaccina-
tion in 2006 or 2008 are shown in Figure 4 and Tables S1 and S2.
Antigenic Site B of Influenza HA
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There is a wide range of avidities among the different plasmas
(Figure 4, panels A and B) and so we normalized the results
relative to wildtype and looked for significantly reduced binding
(Kd increased $30%) to mutants in site A or site B or both
(Figure 4, panels C and D).
The results are summarized in Table 4. Twelve of 18 subjects
vaccinated in 2006 showed reduced binding to site B mutants; 11
of these 12 showed significantly reduced affinity to the mutant
KFK158-160GST. Only 7 of 18 subjects showed reduced binding
to site A mutants; 6 recognizing the mutation K140I. After
vaccination in 2008, 7 of 11 subjects discriminate site B mutants,
and all 7 recognized the KFK158-160GST mutant. Only 2 of the
11 showed reduced binding to site A mutants. Six subjects were
vaccinated in both seasons. All 6 showed reduced binding to site B
mutants in 2006 and 4 of 6 in 2008. Four of the six showed
reduced binding to site A mutants in 2006 but none in 2008.
Human plasma antibodies after vaccination against A/
Wisconsin/67/05 or A/Uruguay/716/07 have low binding
to escape mutant virus EM 1_C02
We measured binding of post-vaccination plasma samples (15
from 2006 and 11 from 2008 vaccinations) to A/Wisconsin/67/05
virus and escape mutants derived from it using the native ELISA
technique, this time capturing virus by binding to sialylated
glycans on turkey erythrocyte ghosts used to coat the wells. Only
virions with native HA will attach to the sialic acids. A/Wisconsin/
67/05 and A/Uruguay/716/07 viruses and escape mutants
derived from Wisconsin/05 virus were titrated with plasma
dilutions to generate binding curves and estimate the overall
apparent affinity (Kdapparent). Our results show that on average
antibodies in human plasma samples in both seasons have reduced
binding to escape mutant virus EM1_C02 but not to EM E05
(Figure 5). These data are in accord with the results of testing
Table 1. Mutations made in antigenic site A and B of A/Oklahoma/309/2006 HA.
Mutations made1 Change Site Charge change Other
NNES121-124ITEG N121I A 0
N122T A 0 Remove glycosylation site
S124G A 0 Remove side chain
N126T N126T A 0 Remove glycosylation site
N133D N133D A 1- Remove glycosylation site
TSSS135-138GSNA T135G A 0 Remove side chain
S137N A 0
S138A A 0
K140I K140I A 1- Same position as E05 escape mutant
RSNNS142-146GPGSG R142G A 1- Remove side chain
S143P A 0
N144S A 0 Remove glycosylation site
S146G A 0 Remove side chain
HL156-157KS H156K B 1- Remove stacking with F159
L157S B 0
KFK158-160GST K158G B 1- Remove side chain
F159S B 0 Same as1_C02 escape mutant
K160I B 1-
NDQI189-192QEQT N186Q B 0
D187E B 0
I190T B 0
A196V A196V B 0
1The amino acids were changed to those of HA of A/Aichi/68.
doi:10.1371/journal.pone.0041895.t001
Figure 2. Expression of wild type and mutant HAs in the baculovirus system. 1. Wild type 309 HA 2. Mutant HL156-157KS 3. Mutant
KFK158-160GST 4. NDQI189-192QEQT 5. A196V 6. N133D 7. TSSS135-138GSNA 8. K140I. Supernatant (25 ml) from a 25 cm2 flask of Sf9 cells infected
with the recombinant baculoviruses expressing wild type and mutant HA was loaded on a 12% SDS-polyacrylamide gel. HA was visualized by
immunoblotting assay with anti-HA tag (YPYDVPDYA) polyclonal antiserum.
doi:10.1371/journal.pone.0041895.g002
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human plasma antibodies against mutant HAs (Figure 4) in that
antibodies in the majority of human plasmas bind to epitopes
within antigenic site B and only a minority to antigenic site A after
vaccination in 2006 and even fewer in 2008.
Discussion
In the early years after the emergence of H3N2 viruses in
humans multiple sequence changes were observed from one
epidemic isolate to next. During the first 10 years (1968–1979), 33
amino acid changes accumulated in HA1 (10.1%) but the vaccine
was changed only 3 times. In recent years the vaccine has been
changed more frequently even though there are fewer changes in
circulating viruses [44]. For example, the only consistent
differences between Wisconsin-like viruses and Brisbane/Uru-
guay-like viruses are G50E in site E and K140I in site A (Table 5).
These two changes were sufficient for the H3N2 component of
vaccine to be changed for season 2008–09.
Antigenic map of H3 HA
Wiley and Skehel proposed a list of amino acids contributing to
each of the five antigenic sites A–E (Figure 1A) [9], but most of
these have not been experimentally tested. The PDB database
contains 4 crystal structures of mAbs bound to X-31 HA (PDB IDs
2VIR, 1QFU, 1E08, 1KEN) and while these confirm the locations
of immunogenic regions, there is some overlap of the classical 5
sites; for example, antibody HC19 contacts 5 amino acids assigned
to Site A as well as 5 listed in Site B [19,20]. As antigenic drift
proceeded from 1968 to 2011, the amino acid sequence changes
are clustered, but not exclusively, into the proposed antigenic sites,
but there are no structural maps of neutralizing epitopes on the
receptor binding domain of newer H3 viruses. We used the panel
of site A and B mutants to partially map the epitopes of the
hmAbs.
The E05 epitope
Mutations K140I and RSNNS142-146GPGSG in antigenic site
A eliminate the binding of E05 but other mutations in antigenic
site A as well as mutations in antigenic site B have no effect
(Table 2). Two escape mutants selected with E05 were isolated;
both had changes at 140 (K140T and K140E). The E05 epitope
therefore appears to be centered around amino acids 140–146.
ELISA data of E05 binding to H3N2 viruses shows high affinity
binding to Wisconsin/67/05 and Oklahoma/309/06, low affinity
binding to California/7/04 and no binding to A/Beijing/89, A/
Panama/99, A/Wyoming/03, A/Uruguay/716/07 or A/Perth/
17/09 (Table 3). Uruguay/07 and Perth/09 viruses share a
mutation K140I in HA1 (Figure 1B), and this is likely to be the
reason why E05 does not bind to them. Wyoming/03 HA has a
mutation N145K compared to Wisconsin/05 HA which is likely to
be the reason for non-binding of E05.
The low binding of E05 to A/California/07/04 is not
immediately explained. The only difference in site A between
California/04 and Wisconsin/05 viruses is N122D with loss of an
N-linked glycan, but this glycan site is present in Oklahoma/309/
06, which binds E05 with high affinity when HA is expressed in
insect cells or the virus is grown in mammalian cells. It is possible
that the glycan added in mammalian or insect cells does not
interfere with E05 binding but the longer complex glycan on the
egg-grown California/07/04 virus blocks E05 binding. We have
not been able to adapt A/Oklahoma/309/06 in chicken eggs to
Figure 3. Quantitation of expressed HA by immunoblotting
assay using anti-HA-tag antibody. Different concentrations of
standard protein GST-HA tag were visualized in the same membrane as
HAs. 1–2, 309 HA (10 ml, 7 ml); 3–4, mutant HA HL156-157KS (10 ml, 7 ml);
5, mock infected; 6–9. GST-HA tag 4 ng, 6 ng, 8 ng, 10 ng, respectively.
The bands were scanned and quantitated using ImageQuant software
(Molecular Dynamics). Amounts of HA were determined from a
standard curve of GST-HA tag fusion protein. Standard curves were
built for each sample of HA.
doi:10.1371/journal.pone.0041895.g003
Table 2. Binding of human monoclonal Abs 1_C02 and E05
to 309 HA and mutants.
HA11 Antigenic site Kd, nM ± SD
1_C02 E05
309 wt Wild type 1.060.2 2.060.1










1His6-tagged wildtype and mutant HA was expressed in insect cells and purified
on a nickel column.
doi:10.1371/journal.pone.0041895.t002
Table 3. Dissociation constants (Kd) for binding of human
monoclonal Abs 1_C02 and E05 to H3N2 viruses.
Kd (nM) ± SD
1_C02 E05
A/Beijing/89 No binding No binding
A/Panama/99 No binding No binding
A/Wyoming/03 .1000 No binding
A/California/04 No binding 97.8626.3
A/Wisconsin/05 2.160.3 6.660.5
A/Oklahoma/06 1.060.2 2.060.3
A/Uruguay/07 No binding No binding
A/Perth/09 No binding No binding
EM 1_C02 (F159S) No binding 6.060.5
EM E05 (K140E/T) 1.960.1 No binding
doi:10.1371/journal.pone.0041895.t003
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test this. In any case, our data suggest that the epitope of
neutralizing antibody E05 is centered on the site A loop of the HA.
The 1_C02 epitope
Antibody 1_C02 binds to A/Wisconsin/67/05 and A/Okla-
homa/309/06 viruses, but not California/07/04 or Uruguay/
716/07. An escape mutant virus selected by 1_C02 (EM1_C02)
contains a single substitution, F159S (Figure 1B), in antigenic site
B. ELISA analysis of mutants in site B shows that mutation
HL156-157KS dramatically decreases the binding of 1_C02, but
the adjacent mutation KFK158-160GST, that includes F159S,
results in only a six fold decrease in affinity. 1_C02 binds to
mutant NDQI189-192QEQT and A196V as well as to wild type.
To try to understand these effects of mutations, we used SWISS-
MODEL [45,46] to model the structure of A/Oklahoma/309/06
HA and its mutants on to the crystal structure of H3 HA of A/
California/04 determined recently in our laboratory. In Califor-
nia/04, H156 is stacked against F159 and also makes contact with
T196. F159 is present in Wisconsin/05 and Oklahoma/309/06
but the change T196A may alter the interactions in this region. In
the energy-minimized model of A/Oklahoma/309/06, F159 is in
the same orientation as in California/07/04, but the orientation of
the side chain of F159 is changed in the HL156-157KS mutant.
We propose that re-orientation of F159 in B-loop in the structure
of HA disrupts the binding of mAb 1_C02. Perhaps the increased
flexibility of GST158-160 compared to KFK allows antibody
1_C02 to bind while it cannot when only F159 is changed, as in
the escape mutant. Sequence changes that might explain why
mAb 1_C02 does not bind A/California/07/04 are N188D,
S193F, T196A and D225N. The only change that could explain
why A/Uruguay/716/07 does not bind 1_C02 is L194P (Table 5).
It seems most likely that antibody 1_C02 interacts with the face of
the 156-loop that is distal to the 190-helix, and that mutations at
F159 and L194 alter the conformation so that 1_C02 cannot bind
although these side chains may not be in direct contact with
antibody.
From these results we conclude that the assignment of antigenic
sites A and B originally made on the X-31 structure apply, at least
approximately, to modern H3 HAs. Crystal structures of antibody
complexes are needed to fully define the E05 and 1_C02 epitopes
but to date we have not obtained suitable crystals.
Antibodies in human plasma samples after vaccination
show decreased binding to mutant HA KFK158-160GST
Thirty years ago, Webster made a large panel of mAbs against
the HA of A/Memphis/1/71 virus and used these to select escape
mutants [11,32]. The results led to the identification of four
antigenic sites [5] with the fifth added by Skehel [6]. Although the
escape mutants showed dramatic loss of binding when tested with
mAbs used for their selection and other mAbs that recognize the
same antigenic site, most of the variants showed no difference
when tested with polyclonal mouse, rabbit or ferret hyperimmune
sera. The exceptions were mutants with changes at 140 and 145
[32]. The conclusion was that site A was immunodominant in the
early H3N2 viruses. We have made a detailed study of recognition
of sites A and B after 2006 and 2008 vaccinations. Of 18 subjects
Figure 4. Analysis of human plasma samples vaccinated in season 2006–07 (H3 component A/Wisconsin/67/05) and season 2008–
09 (H3 component A/Uruguay/716/07). A, B. Overall affinity (Kd 6 St. dev.) of antibodies in human plasma against wt 309 HA and mutants.
Overall affinity labeled as dissociation constant (Kd) of binding of antibodies in plasma from subjects to wild type and mutants in antigenic site A or B;
higher Kd is lower affinity. Kds were measured as described in Materials and Methods and the units are ml plasma in the standard assay. Results are
plotted as mean Kd 6 standard deviation over 3 experiments. C, D. Relative Kd of antibodies in human plasma against mutants relative to binding of
wild type A/OK/309/06 HA. Kds of binding of plasma antibodies to mutants HA are calculated by normalizing Kd of wild type 309 HA to 1.0.
doi:10.1371/journal.pone.0041895.g004
Table 4. Decreased binding to site A and B mutants by human plasma after vaccination.
Mutant Vaccinated 2006–07 (18 subjects) Vaccinated 2008–09 (11 subjects)
Number1 Percent Number Percent
Site B
HL156-157KS 6 33 3 27
KFK158-160GST 11 61 7 64
NDQ189-192QEQT 5 28 2 18
A196V 1 0 0 0
Total subjects binding site B 12 66 7 64
Site A
NNES121-124ITEG 4 22 2 18
N126T 3 17 2 18
N133D 3 17 1 9
TSSS133-138GSNA 2 11 0 0
K140I 6 33 0 0
RSNNS142-146GPGSG 3 17 2 18
Total subjects binding site A 7 39 2 18
Total A, B or both 13 72 8 73
Not A or B 5 28 3 27
1Number of subjects who showed decreased avidity (Kd increased by $30%) to the mutant HA.
doi:10.1371/journal.pone.0041895.t004
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who were given trivalent influenza vaccine in 2006–07, 72%
showed antibodies against sites A, B or both and of these, 66%
showed reduced avidity against site B mutants and 39% against
site A mutants. Plasma of eleven subjects vaccinated in 2008–09
were tested, including six subjects who were vaccinated in both
seasons. 64% showed reduction of binding to site B mutants and
only 18% against site A. Most of the site A response in 2006–07
was to the K140I mutant. In 2008–09 the Uruguay vaccine
component has the K140I mutation so it is not surprising that no
subjects vaccinated in 2008 discriminated the K140I mutant. The
KFK158-160GST mutant was recognized by 11 of the 12 site B
responders in 2006 and 7 of 7 in 2008 (Table 4). There were no
changes in this region of HA1 between Wisconsin/05 and
Uruguay/07 viruses, but our results suggest this is a prime
candidate position for antigenic drift. Indeed, in the following
vaccine strains, A/Perth/16/2009 and A/Victoria/361/2011,
there is a mutation of K158N. Okada et al. [47] described a panel
of mAbs generated by phage-display from a single donor that
included clones that bound to site C of earlier viruses, but for 1997
and 2003 viruses most clones bound site B. Ohshima et al. found
antibodies made by phage display bound a wide variety of epitopes
[38], showing that there are antibodies directed to the minor
antigenic sites that might select mutations in sites C, D and E but
to spread, these would need to be in addition to the
immunodominant site B. HA of A/Perth/16/09 compared to
A/Uruguay/716/07 viruses contains mutations in antigenic site B
(K158N, N189K) but also sites A (S138A) and D (K173Q). Other
changes in the Perth/09 vaccine strain in site A (N144K) site D
I214S, site E (E62K) and site B P194L are not found in other
strains co-circulating with Perth/16/09 or subsequent isolates and
so seem not to be antigenically important. Our results suggest that
in recent years, antigenic site B has been immunodominant over
site A but it appears that the few people with dominant site A
antibodies in 2006 allowed escape and spread of the Uruguay/
Brisbane viruses because of the K140I mutation. In 2008 there
was clear predominance of antibodies against site B in the
population, predictive of the site B change K158N that was later
seen in the Perth16/09 and Victoria/361/11 epidemic strains.
Figure 5. Overall dissociation constants (Kd) of antibodies in human plasma after vaccination. Kd of antibodies in season 2006–2007 (A)
and season 2008–2009 (B). Plasma samples were tested against H3 vaccine viruses A/Wisconsin/67/05 (2006–2007 vaccine) and A/Uruguay/716/07
(2008–2009) and against escape mutant viruses EM 1_C02, EM E05. The median Kd is represented by a horizontal bar, and the p values are from the
Student’s T test.
doi:10.1371/journal.pone.0041895.g005
Table 5. Differences in HA1 sequence between Wisconsin/05 and Uruguay/07 PR8 reassortant vaccine strains.
Amino acid 50 122 140 142 156 186 188 194 196 223
Site C - A A B - B B B -
California/7/04 G (N)1 K R H G N L T V
Wisconsin/67/2005 X-161b G (D)2 K R (Q)3 (V)4 D L A (I)5
Oklahoma/309/2006 E N K R H G D L A V
Brisbane/10/07 E N I R H G D (P)6 A V
Uruguay/716/2007 X-175 E N I (G)7 H G D (P)6 A V
1Changes in parentheses are not present in other isolates from the same season, so may not be antigenically significant. The percent variation analyses were done using
the Influenza Research Database using the ‘‘Analyze Sequence Variation’’ [52].
2All Wisconsin/67/05 sequences have D but 99.7% of 2005/6 isolates have N.
3Q in PR8 reassortants, not isolates from primary chick kidney cells or egg passages.
4V in PR8 ressortants and some other Wisc/67/05 entries; 98.8% of 2005–6 isolates have G.
5I in all Wisc/67/05 entries but 97% of 2005/6 isolates have V.
6P in egg-passaged viruses but not many others.
7G only in reassortant X-175.
doi:10.1371/journal.pone.0041895.t005
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Materials and Methods
Ethics Statement
Written informed consent was obtained from all human subjects
and the study was approved by the Institutional Review Boards of
the University of Oklahoma Health Sciences Center and
Oklahoma Medical Research Foundation.
Viruses and cells
The viruses used in this study were PR8 reassortants A/
California/07/2004 (CDC#2005712034), A/Wisconsin/67/
2005-X161b, and A/Uruguay/716/2007 X-175, all obtained
from CDC, and A/Oklahoma/309/2006, a Wisconsin-like H3N2
isolate. Viruses were grown in embryonated chicken eggs or in
Madin-Darby canine kidney (MDCK) cells in DMEM: Ham’s F12
medium (1:1) with ITS+ (BD Biosciences) and trypsin added as
previously described [48]. Spodoptera frugiperda Sf9 insect cells
(Invitrogen, Cat. No 11496-015) were used as the host for
baculovirus expressing wild type and mutant HAs. Sf9 insect cells
were grown in BD BaculoGoldTM TNM-FH Insect medium (BD
Biosciences).
Antibodies and selection of escape mutants
Human monoclonal antibodies E05 (D3–4) and 1_C02 (D1–7)
have been described [43]. The VH and VL genes were isolated
from single B cells of subjects vaccinated with the 2005–06 or
2006–07 trivalent subunit influenza vaccine, respectively and
cloned into expression vectors to produce IgGs. The expressed
antibodies were purified on Protein A columns. Escape mutants
were selected by incubating A/Wisconsin/67/05-X161b with
1_C02 or E05 mAb and inoculating MDCK cells in a 6-well plate
with varying dilutions of the antibody-virus mixture. Escape
mutants that grew out were passaged three times at limiting
dilution then the HA1 region was sequenced.
Plasmid construction and mutagenesis
The HA gene of A/Oklahoma/309/06 was cloned into plasmid
pCAGGS/MCS [49] as described [50]. For transient expression
of wild type and mutant HA proteins, HeLa or COS cells were
grown in DMEM containing 10% supplemented calf serum
(HyClone), 1% glutamine, 1% sodium pyruvate and 1% PKS
(penicillin, streptomycin, kanamycin sulfate). Wild type and
mutant HA plasmid expression vectors were transfected into the
mammalian cells using LipofectamineTM 2000 transfection
reagent (Invitrogen) according to the manufacturer’s instruction.
To quantify the binding of HA and mutants to human monoclonal
antibodies 1_C02 and E05 [43] and antibodies in human plasma
samples after vaccination we used a Baculovirus expression system.
An insect cell codon-optimized HA gene of A/Oklahoma/309/06
was synthesized by GeneArt (Regensburg, Germany). The
construct included the N-terminal gp67 secretion signal peptide,
then residues 1–512 of HA, the trimerization foldon sequence
[40], thrombin cleavage site and His6-tag. Wild type and mutant
HA were cloned into the pFastBacTM expression vector for
expression in the Bac-to-BacH Baculovirus expression system
(Invitrogen).
To introduce mutations into antigenic sites A and B the
QuickChangeH Site-Directed Mutagenesis Kit (Agilent Technolo-
gies) was used. Mutagenic oligonucleotides were named according
to the original amino acid(s), their position, and the residue(s) that
are changed. The following mutagenic oligonucleotides were used:
Antigenic site A:
forw Bac NNES121-124ITEG: GCACCCTCGAGTTCAT-
CACCGAGGGCTTCAACTGGACCGGTG
forw Bac N126T: ACAACGAGTCCTTCACCTG-
GACCGGTGTCAC
forw Bac N133D: CCGGTGTCACCCAGGACGG-
CACCTCCTCCTC
forw Bac TSSS135-138GSNA: GGTGTCACCCA-
GAACGGCGGCTCCAACGCTTGCAAGCGTCGTTCCAC
forw Bac K140I: CCTCCTCCTCTTGCATCCGTCGTTC-
CAACAACTC






forw Bac KFK158-160GST: AACTGGCTGACC-
CACCTGGGGTCCACGTACCCCGCTCTGAACGTG
forw Bac NDQI189-192QEQT: GCACCACCCCGGCACC-
GACCAAGAGCAGACCTTCCTGTACGCTCAGGC
forw Bac A196V: CCAGATCTTCCTGTACGTT-
CAGGCTTCCGGTCGTATC
All mutations were confirmed by sequence analysis of the whole
HA1 coding region.
Expression of wild type and mutant HAs
To produce recombinant baculovirus containing wild type and
mutant HAs, SF9 insect cells were transfected with the
pFastBacTM HA construct using CellfectinHII reagent (Invitro-
genTM) according to the manufacturer’s protocol. After 72 hours
the supernatant containing P1 viral stock was checked for
expression of HA protein by Western blot analysis. Positive P1
viral stocks were used to generate high-titer P2 baculoviral stocks
that were used for large scale (200 ml) production of HAs. HAs
were purified on a nickel column and tested for correct folding and
processing into HA1 and HA2 by trypsin digestion.
Quantification of expressed wild type and mutant HAs
HAs expressed in the Baculovirus system were quantified by a
Western immunoblotting assay. Protein samples were loaded after
boiling in 26 loading buffer (10 M urea, 4% SDS, 2% b-
mercaptoethanol, 112.5 mM Tris pH 6.8, 0.01% bromphenol
blue) and run in 12% SDS-PAGE. Proteins were electroblotted to
ImmobilonTM-P transfer membrane (Millipore) in buffer (200 mM
CAPS pH 11.0, 10% v/v methanol) for 2 h. To detect HAs we
used goat polyclonal anti-HA tag (YPYDVPDYA, conserved in
H3 HA) antisera (Novus BiologicalsH). The blots were developed
with 10 ml bromochloroindolyl phosphate and nitroblue tetrazo-
lium substrate solution (Sigma). The bands were scanned and
quantitated using ImageQuant software (Molecular Dynamics)
and amounts of HA were determined from a standard curve of
GST-HA tag (YPYDVPDYA) fusion protein.
To measure the amount of HA that was correctly folded we
used a native enzyme-linked immunosorbent assay (ELISA). HA
(50 mg) expressed from SF9 cells was captured on His-TagH
Antibody Plate wells (NovagenH) and incubated overnight at 4uC.
Wells were washed 3 times with PBS, then serial dilutions of
human monoclonal antibodies or heat-inactivated plasma were
added to the wells and incubated at room temperature for 1 hour.
After washing in PBS, alkaline-phosphatase-conjugated goat anti-
human polyvalent immunoglobulin (a, c and m-chain specific)
secondary antibody (Sigma#3313) was bound for 1 hour, the
wells washed free of unbound conjugate and r-nitrophenyl
phosphate substrate (Sigma #104) added. The color was
developed at room temperature for 1 hour and absorbance was
read at 405 nm. Antibody affinities were calculated by nonlinear
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regression (Y = Bmax6X/(Kd+X)) (GraphPad Prism software,) of
ELISA curves plotted from eight dilutions of antibody or human
plasma and represented as the dissociation constant (Kd)
calculated in terms of binding sites (half-IgG). For human plasma,
this is an overall or apparent Kd. A Kd increase greater than or
equal to 1.3 is considered a significant reduction of binding of
antibodies in human plasma samples.
Native ELISA to quantitate antibodies against viruses
We used turkey red cell ghosts solubilized with b-octylpyranoside
to capture native virions for ELISA as previously described [51].
The turkey red blood cells were purchased from Lampire Biological
Laboratories, Inc.
Supporting Information
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